Brief Communication | Published:

VISTA is an inhibitory immune checkpoint that is increased after ipilimumab therapy in patients with prostate cancer

Nature Medicine volume 23, pages 551555 (2017) | Download Citation

Abstract

To date, anti-CTLA-4 (ipilimumab) or anti-PD-1 (nivolumab) monotherapy has not been demonstrated to be of substantial clinical benefit in patients with prostate cancer. To identify additional immune-inhibitory pathways in the prostate-tumor microenvironment, we evaluated untreated and ipilimumab-treated tumors from patients in a presurgical clinical trial. Levels of the PD-L1 and VISTA inhibitory molecules increased on independent subsets of macrophages in treated tumors. Our data suggest that VISTA represents another compensatory inhibitory pathway in prostate tumors after ipilimumab therapy.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

Accessions

Primary accessions

Gene Expression Omnibus

References

  1. 1.

    & Cell 161, 205–214 (2015).

  2. 2.

    & Science 348, 56–61 (2015).

  3. 3.

    et al. Lancet Oncol. 15, 700–712 (2014).

  4. 4.

    et al. N. Engl. J. Med. 366, 2443–2454 (2012).

  5. 5.

    et al. Proc. Natl. Acad. Sci. USA 113, 11919–11924 (2016).

  6. 6.

    et al. Proc. Natl. Acad. Sci. USA 105, 14987–14992 (2008).

  7. 7.

    et al. Cancer Immunol. Res. 1, 229–234 (2013).

  8. 8.

    et al. Clin. Cancer Res. 16, 2861–2871 (2010).

  9. 9.

    et al. J. Exp. Med. 192, 1027–1034 (2000).

  10. 10.

    , , , & Cancer Immunol. Res. 2, 510–517 (2014).

  11. 11.

    et al. Proc. Natl. Acad. Sci. USA 106, 2729–2734 (2009).

  12. 12.

    & Nat. Immunol. 11, 889–896 (2010).

  13. 13.

    et al. Oncogene 34, 5411–5417 (2015).

  14. 14.

    et al. Cancer Immunol. Res. 3, 326–332 (2015).

  15. 15.

    , , & Methods 70, 46–58 (2014).

  16. 16.

    et al. Nat. Biotechnol. 31, 545–552 (2013).

  17. 17.

    et al. Cell 162, 184–197 (2015).

  18. 18.

    , , , & Cancer Res. 57, 3325–3330 (1997).

  19. 19.

    et al. Nat. Commun. 7, 12335 (2016).

  20. 20.

    et al. Cancer Discov. 6, 827–837 (2016).

Download references

Acknowledgements

We thank the clinical and research team for this study, including P. Corn, J. Araujo, B. Chapin, S. Matin, A. Zurita-Saavedra, J. Davis, L. Pisters, and A. Aparicio for treatment and care of patients. We thank M. Campbell for assistance with clinical data collection; L. Xiong, B. Guan, J. Kim, M. Higa, J. Bustillos, D. Ng Tang, and S. Basu for technical support; M. Curran and M. Ai for help with the TRAMP-C2 mouse models; Janssen, CA, for providing the anti-VISTA antibody; and C.G. Liu of the Sequencing & Non-Coding RNA Program for microarray studies. The clinical trial was supported by Bristol-Myers-Squibb (BMS). The research work was also supported by funding from the American Association for Cancer Research (AACR) Stand Up To Cancer–Cancer Research Institute Cancer Immunology Dream Team Translational Research Grant (SU2C-AACR-DT1012; J.P.A., P.S., S.K.S., J.G.); the Prostate Cancer Foundation (PCF) Challenge Grant in Immunology (J.P.A., P.S.); a PCF 2014 Young Investigator Award (S.K.S.); a Conquer Cancer Foundation–American Society of Clinical Oncology (ASCO) 2012 Young Investigator Award (J.G.); Cancer Prevention Research in Texas (CPRIT) RP120108 (P.S.); NIH/NCI R01 CA1633793 (P.S.); and NIH/NCI K12 CA088084 (J.G.) and NIH/NCI P30CA016672 (MD Anderson Cancer Center institutional grant); NIH/NCI P50 CA140388 Prostate Cancer SPORE (P.S., J.P.A., S.K.S., C.J.L., E.E.).

Author information

Affiliations

  1. Department of Genitourinary Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.

    • Jianjun Gao
    • , Lewis Z Shi
    • , Sumit K Subudhi
    • , Jianfeng Chen
    • , Eleni Efstathiou
    • , Christopher J Logothetis
    •  & Padmanee Sharma
  2. Department of Urology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.

    • John F Ward
    •  & Curtis A Pettaway
  3. The Immunotherapy Platform, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.

    • Luis M Vence
    • , Hao Zhao
    • , Hong Chen
    • , James P Allison
    • , Jingjing Sun
    • , Jorge Blando
    •  & Padmanee Sharma
  4. Department of Pathology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.

    • Patricia Troncoso
  5. Department of Immunology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.

    • James P Allison
    •  & Padmanee Sharma
  6. Department of Translational Molecular Pathology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.

    • Ignacio I Wistuba
  7. Janssen Oncology Therapeutic Area, Janssen Research and Development, LLC, Pharmaceutical Companies of Johnson & Johnson, Spring House, Pennsylvania, USA.

    • Manuel A Sepulveda
  8. Department of Surgical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.

    • Jennifer Wargo

Authors

  1. Search for Jianjun Gao in:

  2. Search for John F Ward in:

  3. Search for Curtis A Pettaway in:

  4. Search for Lewis Z Shi in:

  5. Search for Sumit K Subudhi in:

  6. Search for Luis M Vence in:

  7. Search for Hao Zhao in:

  8. Search for Jianfeng Chen in:

  9. Search for Hong Chen in:

  10. Search for Eleni Efstathiou in:

  11. Search for Patricia Troncoso in:

  12. Search for James P Allison in:

  13. Search for Christopher J Logothetis in:

  14. Search for Ignacio I Wistuba in:

  15. Search for Manuel A Sepulveda in:

  16. Search for Jingjing Sun in:

  17. Search for Jennifer Wargo in:

  18. Search for Jorge Blando in:

  19. Search for Padmanee Sharma in:

Contributions

P.S. designed the study; L.Z.S., J.B., L.M.V., J.C., I.I.W., M.A.S., J.S., and H.C. performed the experiments; J.G., J.F.W., C.A.P., L.Z.S., J.C., J.B., L.M.V., I.I.W., J.S., H.Z., J.W., E.E., and P.T. analyzed the data; J.G., P.S., J.P.A., S.K.S., J.W., and C.J.L. drafted the manuscript; and all authors reviewed the final draft of the manuscript.

Competing interests

P.S. and J.P.A. are founders and advisors for Jounce Therapeutics. P.S. and J.P.A. are members of the Parker Institute for Cancer Immunotherapy. P.S. also serves as a consultant for BMS, AstraZeneca, Amgen, and GlaxoSmithKline. J.P.A. is an inventor of intellectual property owned by the University of California, Berkeley, and licensed to BMS and has received royalties from BMS. J.P.A. is also inventor of intellectual property owned by Memorial Sloan Kettering Cancer Center and licensed to Merck. J.G. serves as a consultant for Genentech. I.I.W. serves as a consultant for BMS. E.E. serves as a consultant for Janssen, Bayer, Medivation, Astellas, and Sanofi Takeda.

Corresponding author

Correspondence to Padmanee Sharma.

Supplementary information

PDF files

  1. 1.

    Supplementary Text, Figures and Tables

    Supplementary Discussion, Supplementary Figures 1–10 and Supplementary Tables 1–4

About this article

Publication history

Received

Accepted

Published

DOI

https://doi.org/10.1038/nm.4308

Further reading